IOVA STOCK LOSS: Iovance Biotherapeutics Shareholders are Alerted of Imminent July 14 Class Action Deadline -- Contact BFA Law (NASDAQ:IOVA)

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Issues - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, administering it at authorized treatment centers (ATCs) [3]. - The company claimed that its ATCs would drive demand for Amtagvi; however, there were significant delays in patient treatment timelines and ineffective patient identification, leading to high patient drop-off rates [4]. Financial Performance - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward, citing slow treatment timelines and high patient drop-off rates as contributing factors [5]. - Following the announcement of poor financial results, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].